Skip to content
Cost Curve NewsCost Curve News
  • Home
  • About
  • News
  • Subscribe
19Feb2026
  • Home
  • About
  • News
  • Subscribe
19Feb2026
Cost Curve NewsCost Curve News
Cost Curve News

Moving to MFN Means QALYs — Long Rejected by U.S. Policymakers as Discriminatory — Would Be Used to Set Prices

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
4 hours ago
Keep Reading
Cost Curve News

Oz Continues to Press for MFN ‘Codification’ at PhRMA Event

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
1 day ago
Keep Reading
Cost Curve News

Going Deeper on Another ‘Pharm-to-Conference-Table’ Obesity Offering

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
2 days ago
Keep Reading
Cost Curve News

The Government Is Looking for 340B Rebate Model Feedback As It Resurrects Rulemaking

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
6 days ago
Keep Reading
Cost Curve News

Big Pharma Companies Won Concessions via Dealmaking With Trump. But What Happens to Everyone Else?

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
1 week ago
Keep Reading
Cost Curve News

Pfizer Cut the Price of Certain Forms of Ibrance, Its Blockbuster Breast Cancer Med

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
1 week ago
Keep Reading
Cost Curve News

Can Spending on TrumpRx Be Applied to Insurance Deductibles? It’s Complicated.

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
1 week ago
Keep Reading
Cost Curve News

TrumpRx Continues to Drive Pricing Chatter, With Attention on Generics and GoodRx

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
1 week ago
Keep Reading
Cost Curve News

TrumpRx Is Live. It’s Underwhelming.

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
2 weeks ago
Keep Reading
Cost Curve News

Five Takeaways About the Wild — and Evolving — Cash-Pay Market for Obesity Meds

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
2 weeks ago
Keep Reading
123

Latest Posts

Moving to MFN Means QALYs — Long Rejected by U.S. Policymakers as Discriminatory — Would Be Used to Set Prices

February 19, 2026

Oz Continues to Press for MFN ‘Codification’ at PhRMA Event

February 18, 2026

Going Deeper on Another ‘Pharm-to-Conference-Table’ Obesity Offering

February 17, 2026

The Government Is Looking for 340B Rebate Model Feedback As It Resurrects Rulemaking

February 13, 2026

Big Pharma Companies Won Concessions via Dealmaking With Trump. But What Happens to Everyone Else?

February 12, 2026

Popular

Moving to MFN Means QALYs — Long Rejected by U.S. Policymakers as Discriminatory — Would Be Used to Set Prices

Oz Continues to Press for MFN ‘Codification’ at PhRMA Event

Going Deeper on Another ‘Pharm-to-Conference-Table’ Obesity Offering

The Government Is Looking for 340B Rebate Model Feedback As It Resurrects Rulemaking

Big Pharma Companies Won Concessions via Dealmaking With Trump. But What Happens to Everyone Else?

Pfizer Cut the Price of Certain Forms of Ibrance, Its Blockbuster Breast Cancer Med

Most Viewed
  • CMS Patient-Focused Listening Session Transcripts (3,324)
  • New JAMA Research Shows How Much — and How Rapidly — Part D Plans Have Shifted Drug Costs to Consumers (2,604)
  • Working Out the Strange Math and Weird Consequences of IRA Inflation Penalties (2,160)
  • More IRA Lawsuits Coming, PhRMA Chief Predicts (1,985)
  • Bernie Sanders Wants to Talk to CEOs About US vs ROW Pricing. Bring It On, I Say. (1,953)

Your trusted source for daily updates on drug pricing and policy. Stay informed and ahead of the curve with Cost Curve News.

Latest News

Moving to MFN Means QALYs — Long Rejected by U.S. Policymakers as Discriminatory — Would Be Used to Set Prices

February 19, 2026

Oz Continues to Press for MFN ‘Codification’ at PhRMA Event

February 18, 2026

Subcribe To Newsletter

Subscribe to our newsletter and stay informed about new posts and stay up-to-date on the latest news
Subscribe
© 2026 Cost Curve News | All Rights Reserved
Cost Curve NewsCost Curve News
  • Home
  • About
  • News
  • Subscribe